Preliminary program*
- 06:00 - 10:00 pm, CET
Get Together at the Mercure MOA Berlin
Conference Day 1: Tuesday, November 9th, 2021 8:00 am - 4:45 pm, CET
- 04:45 - 06:30 / 07:00 pm, CET
Poster Session & Exhibition
- 06:30 / 07:00 - 10:00 pm, CET
Evening Event // Poster Session still open for interested parties
Conference Day 2: Wednesday, November 10th, 2021 8:00 am - 04:35 pm, CET
Please note that all times are CET.
Opening: Welcome & Logistics
- 08:00 - 08:15 am
- Opening: Welcome & Logistics
- Dr. Franz-Werner Haas, CEO CureVac
- 08:00 - 08:15 am
Keynote Speaker/Lecture: History of mRNA
- 08:15 - 09:20 am
Session: Delivery
- 09:20 - 10:45 am
- Introduction of Session
- Chair
- mRNA-LNP applications for acute and chronic liver diseases
- Valerie Gouon-Evans, BU School of Medicine, USA
- Influence of lipid nanoparticle delivery chemistry and mRNA modifications on functional protein distribution in mice
- Kathryn A. Whitehead, Carnegie Mellon University, Biomedical Engineering, USA
- RNA Delivery Beyond the Liver: from Gene Silencing to Gene Editing
- Dan Peer, Director of the Laboratory of Precision NanoMedicine Tel Aviv University, Israel
- Lipid Nanoparticles for In Utero mRNA Delivery
- Michael J Mitchell, University of Pennsylvania
Session: Delivery
- 11:05 am - 12:10 pm
- A versatile toolbox for development of RNA LNP-based vaccines, gene therapies and cell therapies
- Euan Ramsay, Precision NanoSystems, Inc.
- Developing mRNA-Based Vaccines and Therapeutics
- Pad Chivukula, Arcturus Therapeutics
- Exosome therapeutics – engineering nature’s nanoparticle system to deliver mRNA and other drugs
- Tony De Fougerolles, Evox Therapeutics
- Oral presentation: Abstract 28
- Gilles Divita
Session: RNA Biology
- 01:00 - 02:05 pm
- Introduction of Session
- Chair
- The influence of codon optimality on gene expression
- Jeff Coller, John Hopkins School of Medicine, USA
- Nucleoside-modified mRNA mediated modulation of organ-specific lymphatic growth and function
- Zoltan Jakus, Semmelweis University, Budapest, Hungary
- Regulation of mRNA translation and decay
- David Bartel, Whitehead Institute for Biomedical Research, USA
- CEO Roundtable
- Stéphane, Ugur/Türeci, Franz
Session: Gene Editing
- 03:20 - 05:00 pm
- Introduction of Session
- Chair
- Writing DNA with RNA
- Cecilia Cotta-Ramusino, Vice President, Head of Platform Tessera Therapeutics
- Translating In Vivo Genome Editing to Bedside
- Laura Sepp-Lorenzino
- Chemo-enzymatic modifications for altering translational and immunogenic properties of mRNA
- Andrea Rentmeister
- Harnessing RNA endonucleases to control gene outputs
- Jeremy E. Wilusz
- Oral abstract presentation: Abstract 33 Correcting metabolic liver diseases by in vivo base editing
- Gerald Schwank
- Concluding Remarks Day 1
- Usually same as opening words
Session: Therapeutics
- 01:00 - 02:05 pm
- Introduction of Session
- Chair
- Nucleoside-Modified Autoantigen-Encoding mRNA-Vaccine as a Novel Approach for Antigen-Specific Tolerance Induction in Autoimmunity
- Christina Krienke, BioNTech
- Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents
- Philip J. Santangelo, Wallace H. Coulter Department of Biomedical Engineering, Emory University, USA
- Tumor specific enzyme assited chemotherapy - a novel approach to specifically eradicate malignant resistant cells
- Mikael Björnstedt, Karolinski Institutet, Department of Laboratory Medicine, Sweden
- Combining antibody and RNA-encoded Interleukin-2 overcomes resistance in MHC class I-deficient cancer
- Jan Beck, BioNTech
- Oral abstract presentation Abstract 19 Transient VEGFA expression using VEGFA mRNA-LNPs induces Biliary epithelial cell-driven liver regeneration in mouse models of liver injury
- Fatima Rizvi
Session: Vaccines
- 09:00 - 10:50 am (inkl. Coffee Break)
- Introduction of Session
- Chair
- Immune responses to SARS-CoV-2 mRNA vaccines in human lymph nodes
- Michela Locci, Perelman School of Medicine, University of Pennsylvania; Penn Institute for Immunology
- IL-1 family members as key regulators of the inflammatory response to RNA vaccines
- Siri Tahtinen, Genentech inc.
- Cancer vaccines candidates based on optimised mRNA-LNP formulations tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells
- Stefaan De Koker, eTheRNA Vice President Discovery
- A VLP-mRNA platform for HIV-1 vaccine development
- Paolo Lusso
Session: Circ RNA
- 01:10 - 02:55 pm
- Introduction of Session
- Chair
- Engineering Circular RNA Therapeutics
- Aravind Asokan, Duke University, Center for Biomolecular and Tissue Engineering, USA
- Harnessing circular RNA biology
- Howard Chang, Stanford University, USA
- The therapeutic potential of oRNA
- Tom Barnes, Orna
- Oral abstract: Abstract 59 Small circular RNA vaccine
- Guizhi Zhu
Session: Manufacturing of mRNA based therapeutics:
- 03:15 - 04:20 pm
- Introduction of Session
- Chair
- Flexible approaches to address mRNA vaccine demand
- Katarina Stenklo, Cytiva
- Enabling cGMP commercial scale manufacturing of therapeutic mRNA at pandemic speed
- Christian Hunzinger, Rentschler Biopharma
- Strategies and considerations for mRNA manufacturing
- Laurens Vergauwen, Merck
- Oral abstract 73: An engineered T7 RNA polymerase that generates immune-silent mRNA
- Nasos Dousis
Closing and passing of the baton
- Scientific Organization Committee
Accepted oral presentations of submitted abstracts will be integrated into the program in a timely manner.
*subject to change and finalisation
